58.79
-1.0688(-1.79%)
Currency In USD
| Previous Close | 59.86 |
| Open | 64.83 |
| Day High | 64.83 |
| Day Low | 58.76 |
| 52-Week High | 68.73 |
| 52-Week Low | 30.82 |
| Volume | 231,700 |
| Average Volume | 379,536.5 |
| Market Cap | 2.04B |
| PE | -13.18 |
| EPS | -4.46 |
| Moving Average 50 Days | 56.05 |
| Moving Average 200 Days | 54.7 |
| Change | -1.07 |
If you invested $1000 in Disc Medicine, Inc. (IRON) since IPO date, it would be worth $570.79 as of August 18, 2025 at a share price of $58.791. Whereas If you bought $1000 worth of Disc Medicine, Inc. (IRON) shares 3 years ago, it would be worth $3,584.83 as of August 18, 2025 at a share price of $58.791.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025
GlobeNewswire Inc.
Jul 21, 2025 12:00 PM GMT
WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious h
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
GlobeNewswire Inc.
Jul 14, 2025 12:30 PM GMT
WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious h
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
GlobeNewswire Inc.
Jun 12, 2025 11:30 AM GMT
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemi